The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.
Details are reported in publications.
Study Type
OBSERVATIONAL
Enrollment
4,837
Intake of nutrients, foods, food groups, beverages; dietary patterns.
Physical activity; smoking; alcohol use; educational level.
Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
SNPs (GWAS)
Cognitive function; dispositional optimism; depression.
Wageningen University, Division of Human Nutrition
Wageningen, Netherlands
Cardiovascular mortality
Death from cardiovascular disease, obtained from causes of death register of Statistics Netherlands
Time frame: From entry into the study (baseline: 2002-2006) through study completion
All-cause mortality
Vital status obtained from municipal population registers in the Netherlands
Time frame: From entry into the study (baseline: 2002-2006) through study completion
Major cardiovascular events
Incidence of fatal and nonfatal cardiovascular events and hospitalisations for cardiac interventions, based on verified information from GP records, hospital records and mortality registers
Time frame: From entry into the study (baseline: 2002-2006) until November 2009
Coronary heart disease
Incidence of fatal and non-fatal coronary heart disease, based on verified information from GP records, hospital records and mortality registers
Time frame: From entry into the study (baseline: 2002-2006) through study completion
Stroke
Incidence of fatal and non-fatal stroke, based on verified information from GP records, hospital records and mortality registers
Time frame: From entry into the study (baseline: 2002-2006) through study completion
Non-cardiovascular mortality
Death from cancer or other non-cardiovascular causes, obtained from causes of death register of Statistics Netherlands
Time frame: From entry into the study (baseline: 2002-2006) through study completion
Type 2 diabetes
Incidence of type 2 diabetes, on basis of self-reported physician diagnosis, use of antidiabetic drugs, or elevated blood glucose
Time frame: From entry into the study (baseline: 2002-2006) until November 2009
Kidney function
Change in serum cystatin C-based estimated glomerular filtration rate
Time frame: From entry into the study (baseline: 2002-2006) until November 2009
Cognitive function
Change in global cognitive function, based on Mini Mental State Examination (MMSE) score
Time frame: From entry into the study (baseline: 2002-2006) until November 2009
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.